View as an RSS Feed
View Derek Lowe's Articles BY TICKER:
ABBV, ABT, ACOR, ACT, AFFY, ALNY, AMGN, ARIA, ARNA, ASTX, AVEO, AZN, BIIB, BIND, BMS, BTIM, CEPH, CNCE, CPRX, DNDN, ELN, ESALY, EXEL, GALE, GE, GNBT, GNVC, GS, GSK, ITMN, JNJ, KVPBQ, LLY, MDVN, MEDX, MNKD, MRK, MTXX, MYGN, NTMD, NVO, NVS, NWBO, OSIR, OSUKF, PFE, PTCT, RBXLF, RBXZF, RDEA, REGN, RHHBY, RNN, RUK, SEPR, SGP, SHPG, SNSS, SNY, SQNM, SVNTQ, TKPHF, TRGT, VNDA, VSTM, WYE
Are New Biopharmas Being Formed Quickly Enough?
Mon, Jan. 26 • Comment!
- A Look At Actavis
- Constellation's Situation
- AbbVie Competes On Price
- AbbVie Competes On Price
A Slight Cubist Complication
- The very day of Merck's bid for Cubist Pharmaceuticals, the company loses a patent case for protection of its flagship drug.
- This can't be welcome news to Merck, since those extra years of revenue would go a long way towards paying off the entire cost of the acquisition.
- You can't always count on a big drug company to be able to discover the drugs it needs (nor a small one, for that matter), but big companies tend to be pretty good at maximizing the revenues that they already have.
- Kickbacks At Sanofi?
Amgen Claims It All
- There's plenty of excitement about PCSK9, the latest LDL-lowering pathway to make it deep into the clinic.
- There are at least five antibodies and one RNAi in development, in a very tight race to the FDA and to the market.
- I don't think that the PCSK9 struggle is going to be decided by the patent lawyers.
- Sanofi Beats The Drum
Bind's Attempts To Remake Chemotherapy
- There's a lot of effort (and a lot of money) going into targeted nanoparticle drug delivery.
- Imagine a drug for lung cancer where all of the dose goes to the lungs, and all of it hits only the cancerous cells.
- Bind, under CEO Scott Minick, has deals with an impressive list of big pharma companies to try to apply their nanoparticle delivery systems to existing drugs.
- There's a vast amount we don't know about these things; the odds are huge that no one is going to be hitting any balls over any fences for a while yet.
Marketing And R&D, Again
- The BBC has an article posted with the title "Pharmaceutical Industry Gets High on Fat Profits", so at least you know where that one's going.
- R&D expenses and SG&A expenses are high in the entire health care sector.
- If Pfizer had done no marketing whatsoever, they would, presumably, have brought in substantially less revenue.
The Case Of Northwest Biotherapeutics
- There have been a lot of strong words exchanged about Northwest Biotherapeutics.
- Small companies that have been unable to interest anyone else in their technologies have a difficult time of it, to be sure. But we don't need to go to conspiracy theories to explain this.
- Wonderful drugs don't get buried by short-sellers. Drugs get buried by data.
- The Most Unconscionable Drug Price Hike I Have Yet Seen
- Google's Calico Moves Into Reality
- Concert's First Drug: Not So Great
- A Look Back At Big Pharma Stocks
- The Instructive Case Of Galena Biopharma
- GlaxoSmithKline's New Sales Practices
- Merck's Aftermath
- Catalyst Pharmaceuticals And Their Business Plan
- So Far So Good For Sanofi, Regeneron's First PCSK9 Phase III
- A Phase III Failure At Eli Lilly - Yes, Again
- Sugammadex's Problems: Is The Merck/Schering-Plough Deal The Worst?
- Prosensa: One Duchenne Therapy Down
- The Arguing Over PTC124 And Duchenne Muscular Dystrophy
- Astex Gets Bought
- A Call For Merck To Cut R&D
- MannKind's Latest Data
- How Much To Develop A Drug? An Update
- Pfizer Rearranges
- Lilly Goes All In On Solanezumab
- Eli Lilly's Alzheimer's Beta-Secretase Inhibitor Hits The Skids